Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859871 | 0.93 | PKM (0.43) | PKMACHETDP1TSHRHTT | |
| SCHEMBL5576909 | 0.92 | PKM (0.43) | PKMACHETDP1TSHRHTT | |
| SCHEMBL14513383 | 0.88 | NPSR1 (0.44) | PKMROCK2ROCK1 | |
| SCHEMBL4861490 | 0.88 | PKM (0.41) | PKMACHETDP1 | |
| SCHEMBL4861365 | 0.87 | PKM (0.46) | PKMACHETDP1HTTPDE4A | |
| SCHEMBL5576790 | 0.86 | DRD2 (0.36) | — | |
| SCHEMBL14513384 | 0.84 | ALDH1A1 (0.34) | TDP1ROCK2 | |
| SCHEMBL4859697 | 0.84 | PKM (0.48) | PKMACHETDP1TSHRHTT | |
| SCHEMBL5312226 | 0.83 | PTGS1 (0.36) | — | |
| SCHEMBL5310169 | 0.83 | PTGS1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007052831-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | REN, GLS, ATP6V1B1 | PKM 2400/4885ACHE 797/4885TDP1 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.